{"success":true,"data":{"pressRelease":{"id":"155097","rtpr_id":"nGNX8bvxp2-20260929","ticker":"OCGN","exchange":"NASDAQ","all_tickers":["OCGN"],"title":"Ocugen to Participate in Upcoming October Investor and Industry Conferences","author":"Globe Newswire","published_at":"2026-09-29T11:02:00.108Z","article_body":"MALVERN, Pa., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the\nCompany) (NASDAQ: OCGN), a pioneering biotechnology company developing gene\ntherapies for blindness diseases, today announced that members of its\nexecutive leadership team will present at two upcoming investor and industry\nconferences.\n\nH.C. Wainwright: Biotech on Tap 2026\nLocation: EY Auditorium, Munich, Germany\nDate: Thursday, October 1, 2026\nTime: 1:45–2:30 p.m. CEST\nFormat: Panel discussion\nTitle: Structured Finance Solutions: Royalty, Credit and Other Alternative\nFinancing Options for Life Sciences\nPresenter: Session Moderator — Dr. Shankar Musunuri, Chairman, CEO, and\nCo-Founder, Ocugen\n\nCell & Gene Meeting on the Mesa 2026\nLocation: Arizona Biltmore, Phoenix, AZ\nDate: Tuesday, October 6, 2026\nTime: 2:15–3:15 p.m. MST\nFormat: Panel discussion\nTitle: Navigating the Road to Approval, Commercialization, and the Future of\nCell and Gene Therapy\nPresenter: Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder, Ocugen\n\nAbout Ocugen, Inc.\nOcugen, Inc. is a pioneering biotechnology company developing gene therapies\nfor blindness diseases. The Company’s breakthrough modifier gene therapy\nplatform has the potential to address significant unmet medical needs across\nlarge patient populations through a gene-agnostic approach. Unlike traditional\ngene therapies and gene-editing technologies that target a single gene\nmutation, Ocugen’s modifier gene therapies are designed to address the\nunderlying disease biology by restoring balance across multiple gene networks.\nThe Company is currently advancing programs for inherited retinal diseases and\nother causes of blindness that affect millions worldwide, including retinitis\npigmentosa, Stargardt disease, and geographic atrophy, an advanced form of dry\nage-related macular degeneration. Discover more at www.ocugen.com and follow\nus on LinkedIn\n(https://www.globenewswire.com/Tracker?data=nm6tD7JwObAjH99a49t46G6-plkLyt065oChocmSbIv2cM9VB53vVQYnlLFU5AZtb-AkyaVC5yjalvhgWleC5JvqEWvVuOSFwfaMtbeYQeY=)\nand X\n(https://www.globenewswire.com/Tracker?data=KqCGO52Jt-fXkw0SJcsBoN6IH5pzpdYv9Dx2A81tZhBazvnJsmjVAiynwUm5mzgl).\n\nCautionary Note on Forward-Looking Statements\nThis press release contains forward-looking statements within the meaning of\nThe Private Securities Litigation Reform Act of 1995, which are subject to\nrisks and uncertainties. We may, in some cases, use terms such as\n“predicts,” “believes,” “potential,” “proposed,”\n“continue,” “estimates,” “anticipates,” “expects,”\n“plans,” “intends,” “may,” “could,” “might,” “will,”\n“should,” or other words that convey uncertainty of future events or\noutcomes to identify these forward-looking statements. Such statements are\nsubject to numerous important factors, risks, and uncertainties that may cause\nactual events or results to differ materially from our current expectations.\nThese and other risks and uncertainties are more fully described in our\nfilings with the Securities and Exchange Commission (SEC), including the risk\nfactors described in the section entitled “Risk Factors” in the quarterly\nand annual reports that we file with the SEC. Any forward-looking statements\nthat we make in this press release speak only as of the date of this press\nrelease. Except as required by law, we assume no obligation to update\nforward-looking statements contained in this press release whether as a result\nof new information, future events, or otherwise, after the date of this press\nrelease.\n\nContacts:\n\nInvestors:\nCandice Masse\nastr partners\ncandice.masse@astrpartners.com\n\nMedia:\nChris Clark\nchris.clark@ocugen.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/18d074ba-efcd-41fd-94bc-e3bf2cc4069d)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX8bvxp2-20260929","title":"Ocugen to Participate in Upcoming October Investor and Industry Conferences","author":"Globe Newswire","ticker":"OCGN","created":"2026-09-29T11:02:00.108Z","tickers":["OCGN"],"exchange":"NASDAQ","article_body":"MALVERN, Pa., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the\nCompany) (NASDAQ: OCGN), a pioneering biotechnology company developing gene\ntherapies for blindness diseases, today announced that members of its\nexecutive leadership team will present at two upcoming investor and industry\nconferences.\n\nH.C. Wainwright: Biotech on Tap 2026\nLocation: EY Auditorium, Munich, Germany\nDate: Thursday, October 1, 2026\nTime: 1:45–2:30 p.m. CEST\nFormat: Panel discussion\nTitle: Structured Finance Solutions: Royalty, Credit and Other Alternative\nFinancing Options for Life Sciences\nPresenter: Session Moderator — Dr. Shankar Musunuri, Chairman, CEO, and\nCo-Founder, Ocugen\n\nCell & Gene Meeting on the Mesa 2026\nLocation: Arizona Biltmore, Phoenix, AZ\nDate: Tuesday, October 6, 2026\nTime: 2:15–3:15 p.m. MST\nFormat: Panel discussion\nTitle: Navigating the Road to Approval, Commercialization, and the Future of\nCell and Gene Therapy\nPresenter: Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder, Ocugen\n\nAbout Ocugen, Inc.\nOcugen, Inc. is a pioneering biotechnology company developing gene therapies\nfor blindness diseases. The Company’s breakthrough modifier gene therapy\nplatform has the potential to address significant unmet medical needs across\nlarge patient populations through a gene-agnostic approach. Unlike traditional\ngene therapies and gene-editing technologies that target a single gene\nmutation, Ocugen’s modifier gene therapies are designed to address the\nunderlying disease biology by restoring balance across multiple gene networks.\nThe Company is currently advancing programs for inherited retinal diseases and\nother causes of blindness that affect millions worldwide, including retinitis\npigmentosa, Stargardt disease, and geographic atrophy, an advanced form of dry\nage-related macular degeneration. Discover more at www.ocugen.com and follow\nus on LinkedIn\n(https://www.globenewswire.com/Tracker?data=nm6tD7JwObAjH99a49t46G6-plkLyt065oChocmSbIv2cM9VB53vVQYnlLFU5AZtb-AkyaVC5yjalvhgWleC5JvqEWvVuOSFwfaMtbeYQeY=)\nand X\n(https://www.globenewswire.com/Tracker?data=KqCGO52Jt-fXkw0SJcsBoN6IH5pzpdYv9Dx2A81tZhBazvnJsmjVAiynwUm5mzgl).\n\nCautionary Note on Forward-Looking Statements\nThis press release contains forward-looking statements within the meaning of\nThe Private Securities Litigation Reform Act of 1995, which are subject to\nrisks and uncertainties. We may, in some cases, use terms such as\n“predicts,” “believes,” “potential,” “proposed,”\n“continue,” “estimates,” “anticipates,” “expects,”\n“plans,” “intends,” “may,” “could,” “might,” “will,”\n“should,” or other words that convey uncertainty of future events or\noutcomes to identify these forward-looking statements. Such statements are\nsubject to numerous important factors, risks, and uncertainties that may cause\nactual events or results to differ materially from our current expectations.\nThese and other risks and uncertainties are more fully described in our\nfilings with the Securities and Exchange Commission (SEC), including the risk\nfactors described in the section entitled “Risk Factors” in the quarterly\nand annual reports that we file with the SEC. Any forward-looking statements\nthat we make in this press release speak only as of the date of this press\nrelease. Except as required by law, we assume no obligation to update\nforward-looking statements contained in this press release whether as a result\nof new information, future events, or otherwise, after the date of this press\nrelease.\n\nContacts:\n\nInvestors:\nCandice Masse\nastr partners\ncandice.masse@astrpartners.com\n\nMedia:\nChris Clark\nchris.clark@ocugen.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/18d074ba-efcd-41fd-94bc-e3bf2cc4069d)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-09-29T11:02:00.145417937Z","server_sent_at_ms":1790679720145},"received_at":"2026-09-29T11:02:00.206Z","source_url":null},"analysis":{"id":"143840","press_release_id":"155097","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Ocugen announced its executive leadership will present at two October investor and industry conferences.\n\nCEO Dr. Shankar Musunuri will moderate a panel on alternative life-sciences financing at H.C. Wainwright's Biotech on Tap in Munich on October 1, and speak on cell and gene therapy commercialization at the Cell & Gene Meeting on the Mesa in Phoenix on October 6.\n\nThe release contains no new clinical, regulatory, or financial information and is routine investor-relations scheduling.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine conference participation -- no incremental news; suppress unless panel commentary surfaces."},"keyFigures":{},"namedEntities":{"people":[{"name":"Dr. Shankar Musunuri","role":"Chairman, CEO, and Co-Founder"}],"products":[],"companies":[{"name":"Ocugen, Inc.","ticker":"OCGN","relationship":"filer"},{"name":"H.C. Wainwright","relationship":"conference host"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine announcement of executive participation in two investor/industry conference panel discussions. No new data, financials, or corporate developments disclosed."},"tickerRelevance":{"others":[],"primary":"OCGN"},"globalImportance":8,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"routine-conference-scheduling","issuerAuthored":true,"retailFavoriteBoost":"moderate -- OCGN has retail interest"}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Ocugen announced its executive leadership will present at two October investor and industry conferences.\n\nCEO Dr. Shankar Musunuri will moderate a panel on alternative life-sciences financing at H.C. Wainwright's Biotech on Tap in Munich on October 1, and speak on cell and gene therapy commercialization at the Cell & Gene Meeting on the Mesa in Phoenix on October 6.\n\nThe release contains no new clinical, regulatory, or financial information and is routine investor-relations scheduling.","key_figures":{},"named_entities":{"people":[{"name":"Dr. Shankar Musunuri","role":"Chairman, CEO, and Co-Founder"}],"products":[],"companies":[{"name":"Ocugen, Inc.","ticker":"OCGN","relationship":"filer"},{"name":"H.C. Wainwright","relationship":"conference host"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-29T11:02:05.160Z","global_importance":8,"audience_relevance":15,"importance_components":{"tickerTier":"small-cap","eventGravity":"routine-conference-scheduling","issuerAuthored":true,"retailFavoriteBoost":"moderate -- OCGN has retail interest"}},"durationMs":4929,"modelName":"glm-5.3-flashx"}}